

Review

Open Access



Pancreaticoduodenectomy for gastric cancer

Rie Makuuchi, Tomoyuki Irino, Yutaka Tanizawa, Etsuro Bando, Taiichi Kawamura, Masanori Terashima

Division of Gastric Surgery, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.

Correspondence to: Dr. Masanori Terashima, Division of Gastric Surgery, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-Cho, Sunto-Gun, Shizuoka 411-8777, Japan. E-mail: m.terashima@scchr.jp

How to cite this article: Makuuchi R, Irino T, Tanizawa Y, Bando E, Kawamura T, Terashima M. Pancreaticoduodenectomy for gastric cancer. *J Cancer Metastasis Treat* 2018;4:26. <http://dx.doi.org/10.20517/2394-4722.2018.15>

Received: 1 Mar 2018 **First Decision:** 4 Apr 2018 **Revised:** 10 Apr 2018 **Accepted:** 21 May 2018 **Published:** 7 Jun 2018

Science Editors: Masayuki Watanabe **Copy Editor:** Jun-Yao Li **Production Editor:** Huan-Liang Wu

Abstract

Pancreaticoduodenectomy (PD) is performed to achieve an R0 resection for gastric cancer with pancreatic and/or duodenal invasion. Several retrospective case series have been published, but the sample cohorts in each study were heterogeneous and small. Moreover, the absence of prospective studies results in a lack of solid evidence that will help determine who can benefit from this procedure. Although the morbidity and mortality of PD have been reported by most studies to be acceptable and that the procedure is feasible, these remained to be much higher than those of standard gastrectomy. Therefore, careful selection of patients should be considered. Based on a review of previous case series and our own experience, PD appears to be beneficial to patients with gastric cancer with pancreatic invasion when R0 resection is possible. In addition, multidisciplinary treatment such as neoadjuvant chemotherapy, is anticipated to improve survival. Nevertheless, considering that prospective randomized studies are difficult to perform, a large-scale multicenter retrospective cohort study is required to evaluate this highly invasive procedure.

Keywords: Gastric cancer, pancreaticoduodenectomy, multivisceral resection

INTRODUCTION

Gastric cancer is the fifth most common cancer and is the third leading cause of cancer deaths worldwide^[1]. Its incidence is higher in Eastern Asia, including Japan, Korea, and China, than in Western countries. Although approximately 50% of the patients in Japan are diagnosed during the early stages of gastric cancer, several patients are diagnosed in the advanced stages^[2]. For gastric cancer treatment, radical surgical resection with lymph node dissection is the established standard and complete surgical resection without residual disease (R0 resection) is the cornerstone. For tumors that invade adjacent organs, combined resection is necessary for achieving complete tumor clearance.



© The Author(s) 2018. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



The pancreas is the organ most frequently invaded by gastric cancer^[3-6]. When a tumor and/or lymphadenopathy invades the pancreatic head or infiltrates the duodenum, pancreaticoduodenectomy (PD) is the only possible treatment for achieving R0 resection. However, PD is a highly invasive procedure that cannot be performed on all patients. Since the first reported case of a patient who underwent PD for gastric cancer in 1978^[7], all case series published^[8-17] were retrospective and single-center studies and no prospective study has been done. Because of the limited number of patients and heterogeneous data of the studies, definite indications for PD have not been established. Here we reviewed the literature on PD for gastric cancer and our own experience to clarify short- and long-term outcomes and the role of PD in gastric cancer.

METHODS OF LITERATURE SEARCH

We conducted a literature search on PubMed using keywords “gastric cancer”, “pancreaticoduodenectomy”, and “multivisceral resection” considering articles published until November 2017. We excluded inaccessible abstracts or articles not written in English. In addition, we reviewed patients who underwent distal or total gastrectomy with PD at Shizuoka Cancer Center (Shizuoka, Japan) between September 2002 and December 2015. We collected patients’ characteristics and pathological and surgical findings from our database and individual patients’ electronic medical records. In addition, we statistically analyzed our data using R Statistics version 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria). Furthermore, we calculated 5-year survival rates using the Kaplan-Meier method and compared them between the groups using the log-rank test. The statistical significance of data was defined as $P < 0.05$.

SHORT-TERM SURGICAL OUTCOMES

PD is a highly invasive procedure that requires high surgical skills. When Buchholtz *et al.*^[7] first reported PD for gastric cancer in 1978, they concluded that this treatment should not be performed because of the unacceptable risk without an additional and greater degree of palliation or likelihood of cure; however, they did not discuss their reasons in detail. Several studies have demonstrated short-term surgical outcomes of PD, including intraoperative blood loss, operation time, morbidity, and mortality [Table 1]^[8-17]. The median amount of blood loss was reported to be > 1000 mL and the median operation time was as long as 7 h.

Although several studies have concluded that PD for gastric cancer is feasible in terms of safety, the incidence of postoperative complications ranged widely from 22% to 74%, probably because of discrepancies in the definitions of complication. No study defined the exact criteria for postoperative complications because many of these reports were published before the definitive criteria for postoperative complications, the Clavien–Dindo classification^[18], were established. The mortality rate of PD was reported to be from 0% to 13%; however, the definition of the period of operative death differed among the studies; some defined mortality as death from any cause within 30 days after surgery, whereas the others did not mention the period. The study by Nunobe *et al.*^[14], who defined mortality as death from any cause before discharge, reported the highest mortality of 13%.

Although Min *et al.*^[16] reported the lowest complication rate of 22% among the reported rates of the previous studies, they also demonstrated one of the highest mortality rates, which was 11%. These results meant that half of the patients who suffered from postoperative complications died; this 50% mortality rate among patients who suffered postoperative morbidity seemed to be a bit high, which was possibly due to the variable definitions of all the complications. At the same time, Yonemura *et al.*^[8] reported a 23% incidence of pancreatic fistula, but did not report the incidence of all complications.

Saka *et al.*^[11] reported the highest complication rate of 74%, with pancreatic fistula being the most frequent in 44% of patients; all patients recovered with conservative management and none reported operation-related

Table 1. Summary of studies on pancreaticoduodenectomy for gastric cancer

Authors	Patients (n)	Morbidity	Mortality	Blood loss (mL)	Operation time (min)	Overall survival	P value	Subset analysis	Overall survival by subset analysis	P value by subset analysis	
Yonemura <i>et al.</i> ^[8]	PD = 26	23%*	0%	1600	288	NR	NR	Duodenal inv. PD vs. non-cases only	NR	NS	
	Non-PD = 63	3%*	3%	1200	216	NR		pN3 cases only	PD vs. non-PD	33% vs. 17% (5-year)	< 0.05
								Pancreatic inv. PD vs. non-cases only	PD vs. non-PD	55% vs. 0% (5-year)	< 0.01
Hirose <i>et al.</i> ^[9]	PD = 10	70%	0%	1402	580	40% (5-year)	NS	Stage IV PD vs. non-cases only	PD vs. non-PD	44% vs. 20% (5-year)	< 0.05
	Non-PD = 69	32%	0%	563	330	45% (5-year)		pSI cases only	PD vs. non-PD	19 vs. 9 months (MST)	0.0478**
Ajisaka <i>et al.</i> ^[10]	PD = 22	NR	NR	NR	NR	35% (5-year)	NS	pN3 cases only	PD vs. non-PD	19 vs. 20 months (MST)	NS
	Non-PD = 47	NR	NR	NR	NR	16% (5-year)		Length of duodenal inv.	< 30 mm vs. ≥ 30 mm	21.2% vs. 26% (5-year)	NS
								Duodenal inv. type	Mucosal type vs. submucosal type vs. nodal type	28% vs. 9.2% vs. 0% (5-year)	0.058 ^a , < 0.001 ^b , 0.304 ^c
Saka <i>et al.</i> ^[11]	PD = 23	74%	0%	1600	480	34% (5-year)		RO cases only	PD vs. non-PD	37.3% vs. 33.8% (5-year)	NS
	Non-PD = 45	NR	NR	NR	NR	28% (5-year)		RO vs. R1/2	RO vs. R1/2	47.4% vs. 0% (5-year)	0.035
Lee <i>et al.</i> ^[12]	PD = 25	32%	0%	NR	349.5	15.8% (5-year)	NR				
Chan <i>et al.</i> ^[13]	PD = 7	43%	0%	600	480	60% (5-year)	NR				
Nunobe <i>et al.</i> ^[14]	PD with U7 LN = 23	13%*	13%	1700	535	7.7% (5-year)	0.014	Pancreatic inv. pattern	Tumor inv. vs. lymph node inv.	NR	0.324
	PD with ≤ 6 LN = 8	12.5%*	12.50%	1731	499	50% (5-year)		Tumor inv. cases only	U 7 LN vs. M 6 LN	NR	0.692
								Lymph inv. cases only	U 7 LN vs. M 6 LN	NR	< 0.001
Wang <i>et al.</i> ^[15]	PD = 17	71%	0%	NR	NR	34% (3-year)	0.0064				
	Non-PD = 36	NR	NR	NR	NR	6% (3-year)					
Min <i>et al.</i> ^[16]	PD = 9	22%	11.10%	NR	420	0% (5-year)	0.013				
	Non-PD = 58	31%	0%	NR	254	27.4% (5-year)					
Ryu <i>et al.</i> ^[17]	PD = 16	31.3%	6.30%	NR	NR	12.5% (5-year)	NR	RO vs. R1/2	RO vs. R1/2	15.4% vs. 0% (5-year)	0.458
								Postoperative chemo	Chemo vs. no-chemo	22.2% vs. 0% (5-year)	< 0.01
Present study	PD = 24	87.5% [§]	8.3%	1218	449	27.5% (5-year)	NR	RO vs. R1	RO vs. R1	38.8% vs. 0% (5-year)	0.078
								RO cases only	Pancreatic inv. vs. duodenal inv. diff. vs. undiff.	54.5% vs. 0% (5-year)	0.048
										68.6% vs. 0% (5-year)	0.004

*Pancreatic fistula only; **by Wilcoxon test; ^amucosal vs. submucosal type; ^bmucosal vs. nodal type; ^csubmucosal vs. nodal type; [§]Clavien-Dindo Grade II or more. PD: pancreaticoduodenectomy; NR: not reported; LN: lymph node metastasis; NS: not significant; MST: median survival time; OS: overall survival; inv.: invasion; chemo: chemotherapy; diff.: differentiated adenocarcinoma; undiff.: undifferentiated adenocarcinoma

death. Nunobe *et al.*^[14] featured the largest number of patients, including 31 patients with gastric cancer who underwent PD. Although their center is one of the largest high-volume centers in Japan, with > 300 cases of gastrectomy performed during one year, the mortality rate of PD was as high as 13%. The most frequently observed complication was pancreatic leakage (13%), followed by intraabdominal abscess (6%) and colitis (6%); however, they did not report the rates of the other postoperative complications.

In our center, 24 gastric cancer patients underwent PD from 2002 to 2016; 19 patients underwent distal gastrectomy and 5 patients underwent total gastrectomy. Differentiated adenocarcinoma was noted in 15 patients and undifferentiated adenocarcinoma was noted in nine. The median blood loss was 1218 mL and the median operative time was 449 min. R0 resection was performed on 17 patients (70.8%) and R1 was performed on 7 patients (29.2%) owing to positive lavage cytology (CY1). There were no patients with tumor-positive resection margins. Four patients had a small number of peritoneal deposits adjacent to the stomach, which were completely resected during operation.

SURVIVAL BENEFITS OF PD FOR PATIENTS WITH GASTRIC CANCER

Several studies have evaluated the survival outcomes of patients undergoing PD for gastric cancer [Table 1]. However, conflicting results were reported, mainly because of heterogeneous data and small sample size in each study.

According to studies that evaluated multivisceral resection for gastric cancer clinically invading the adjacent organs (T4b) or for pathologic T4b gastric cancer, R0 resection and lymph node status were the independent prognostic factors^[3,4,6,19]; however, few studies have shown poor survival outcomes for patients who underwent combined resection of the pancreas or a tumor invading the pancreas^[16,20]. It is important to note that, in these studies, the number of patients who underwent PD was few or unknown. Among these, the retrospective study on the prognostic factors in patients with T4b gastric cancer by Min *et al.*^[16] reported the highest number of patients who underwent PD; there were a total of 243 T4b gastric cancer patients, including 67 patients that had tumor invasion to the pancreas. In that study, pancreatic invasion was identified as an independent unfavorable prognostic factor by multivariate analysis. Moreover, among the operation methods used for pancreatectomy in the pancreatic invasion group, the PD group ($n = 9$) had a significantly lower 5-year survival rate, compared with that of the other pancreatectomies group ($n = 58$) (0% vs. 27.4%, $P = 0.013$). Therefore, they did not recommend PD for T4b gastric cancer invading the pancreatic head.

In contrast, studies that compared PD and gastrectomy alone for T4b gastric cancer have found a therapeutic benefit of PD. Wang *et al.*^[15] evaluated 53 patients with gastric cancer and pancreaticoduodenal region involvement and found that PD improved the 3-year survival rate, compared with that of palliative gastrectomy (34% vs. 5.6%, $P = 0.0064$). Hirose *et al.*^[9] showed that among patients with gastric cancer invading the pancreatic head, the median survival time (MST) was better in the PD group than in the palliative gastrectomy group (19 months vs. 9 months, $P = 0.0478$). Yonemura *et al.*^[8] also demonstrated that, compared with gastrectomy alone, PD with right hemicolectomy improved the 5-year survival rate of patients with pancreatic invasion (55% vs. 0%, $P < 0.01$). Saka *et al.*^[11] investigated 23 patients who underwent R0 resection with PD for gastric cancer macroscopically infiltrating the pancreatic head and showed that the 5-year survival rate was significantly better in patients without incurable factors, such as para-aortic lymph node metastasis, positive lavage cytology (CY1), and peritoneal dissemination, than in those with incurable factors (47.4% vs. 0%, $P = 0.035$). It should be noted that in that study, CY1 cases were treated as R0 resection, which is considered an R1 resection according to the 7th edition UICC TNM classification.

In patients undergoing PD, there are two patterns of invasion to the pancreatic head, including direct invasion of the primary tumor and invasion via metastatic lymph nodes. Although most studies have not investigated survival according to the pattern of pancreatic invasion, the study by Nunobe *et al.*^[14] showed




Figure 1. OS curve of 24 patients. There were 17 patients who underwent R0 resection and 7 patients who underwent R1 resection. The 5-year OS was better in patients who underwent R0 resection (38.8%) than in those who underwent R1 resection (0%), although the difference was not statistically significant ($P = 0.078$). OS: overall survival

no difference in survival between these two patterns of invasion ($P = 0.324$). According to these studies, if R0 resection is considered possible, PD should be performed for patients with either primary tumor or metastatic lymph node invasion to the pancreatic head.

Regarding the therapeutic benefit of PD for patients with tumors infiltrating the duodenum, no unified view has been obtained so far. Yonemura *et al.*^[8] reported a survival benefit of PD over gastrectomy for T4b tumors, but not for tumors with duodenal invasion. Ajisaka *et al.*^[10] evaluated 69 gastric cancer patients with duodenal invasion; among them, 22 patients underwent PD and 47 patients underwent gastrectomy alone. When a negative resection margin was achieved (i.e., R0 resection), the 5-year survival rates were almost the same (37.3% for PD vs. 33.8% for gastrectomy alone), although patients who underwent PD had more frequent adjacent tissue infiltration and significantly longer extent of duodenal invasion. They also found that survival was worse when duodenal invasion was from lymph node metastasis than from the primary tumor. Therefore, they concluded that curative PD for gastric cancer improved the survival of patients with duodenal invasion, except when duodenal invasion was of the nodal type.

Two studies have investigated the survival benefit of PD for patients with extensive lymph node metastases. Yonemura *et al.*^[8] reported that PD improved the 5-year survival rate of patients with N3 lymph node metastasis (33% vs. 17%, $P < 0.05$). They used the first English edition of the Japanese Classification of Gastric Carcinoma^[21], in which there were five N stages, with N3 referring to metastases in the hepatoduodenal, pre- and retropancreatic, and superior mesenteric nodes. In contrast, Hirose *et al.*^[9] demonstrated that compared with palliative gastrectomy, PD had a tendency to not improve MST for patients with N3 lymph node metastases (19 months vs. 20 months, the differences were not significant). Therefore, it is difficult to reach a conclusion from these opposing results.

The other reported factors associated with better survival in patients who underwent PD included well-differentiated histologic type^[15], adjuvant intravenous chemotherapy^[17], and metastatic lymph nodes less than seven^[14]. Based on our experience of patients who underwent PD for gastric cancer, the 5-year overall survival (OS) rate was 27.5% and the MST was 17.2 months. The 5-year OS rate was 38.8% in patients who underwent R0 resection ($n = 17$) and 0% in those who underwent R1 resection ($n = 7$), although this difference was not statistically significant ($P = 0.078$), possibly due to the small sample size [Figure 1]. The OS curves of patients who underwent R0 resection are shown in Figure 2. The 5-year survival rate was significantly higher in patients with predominantly pancreatic invasion than in those with duodenal




Figure 2. OS curves of 17 patients who underwent R0 resection. The 5-year OS rate was significantly better (A) in patients with pancreatic invasion than in those with duodenal invasion (54.5% vs. 0%; $P = 0.048$) and (B) in patients with differentiated tumors than in those with undifferentiated tumors (68.6% vs. 0%; $P = 0.004$). OS: overall survival

invasion ($n = 11$, 54.5% vs. $n = 6$, 0%; $P = 0.048$) [Figure 2A]. Likewise, the 5-year OS rate was significantly higher in patients with differentiated tumors than in those with undifferentiated tumors ($n = 10$, 68.6% vs. $n = 7$, 0%; $P = 0.004$) [Figure 2B]. The univariate analysis of patients who underwent R0 resection is shown in Table 2.

Although conclusive results are difficult to obtain from previous studies, which had limited number of patients and heterogeneous data, it appeared that R0 resection is the minimum requirement for cure and that PD should not be performed in cases of CY1. In addition, tumors with duodenal invasion have little chance for cure; therefore, in cases with a positive resection margin, palliative surgery followed by chemotherapy or radiotherapy may be an alternative to PD. However, evidence proving this hypothesis is lacking.

DIAGNOSIS OF PANCREATIC INVASION BEFORE OR DURING OPERATION

Intraoperative diagnosis of tumor invasion to the pancreas has been reported to be difficult, with an accuracy rate ranging from 39% to 56.7%^[5,6,22]. Adhesions secondary to desmoplastic reaction or tumor inflammation can be mistaken for local invasion^[23], which could lead to patients being subjected to unnecessary multivisceral resection and result in increased morbidity and mortality without oncological

Table 2. Univariate analysis of the factors affecting the survival of patients who underwent R0 resection

Covariates	n	5-year OS (%)	MST (months)	P value
Reason for PD				
Pancreatic invasion	11	54.5	-	0.048
Duodenal invasion	6	0	26.4	
Macroscopic type				
Non-type 4	15	40	31.6	0.551
Type 4	2	0	2.1	
Histological type				
Differentiated	10	68.6	-	0.004
Undifferentiated	7	0	10	
Type of gastrectomy				
DG	14	35.7	31.6	0.68
TG	3	66.7	-	
pT stage				
T1-3	7	57.1	-	0.339
T4	10	25	23.1	
pN stage				
N0/1/2	10	40	26.4	0.813
N3	7	38.1	45.6	
pStage				
Stage II-III	13	35.2	31.6	0.652
Stage IV	4	50	23.1	

OS: overall survival; MST: median survival time; PD: pancreaticoduodenectomy; DG: distal gastrectomy; TG: total gastrectomy

benefit. In our experience, pancreatic invasion from a tumor was suspected intraoperatively in 11 patients, but it was confirmed pathologically in only 8 patients (72.7%). In patients who were suspected to have pancreatic invasion of the tumor, the 5-year survival rate tended to be poor in patients with pathologically positive invasion than in those with pathologically negative invasion (66.7% vs. 12.5%, $P = 0.150$).

Preoperative imaging, including multidetector computed tomography (MDCT)^[24] and endoscopic ultrasound (EUS)^[25], may facilitate identification of pathological invasion. However, the accuracy of MDCT and EUS for the assessment of pathological tumor depth was low and varied between 77.1%–88.9% and 65%–92.1%, respectively^[26].

PREOPERATIVE CHEMOTHERAPY

Neoadjuvant chemotherapy had been described by only one study; Chan *et al.*^[13] reviewed nine patients with locally advanced gastric cancer involving the duodenum and/or pancreatic head. All patients underwent diagnostic laparoscopy or exploratory laparotomy prior to the surgery to exclude peritoneal metastases. Two patients did not undergo PD because of disease progression with liver metastasis and patient refusal. Of the seven remaining patients who underwent PD, three did not receive neoadjuvant chemotherapy due to patient refusal and bleeding from the tumor. Although the study involved quite a small number of patients and its follow-up was short, it showed a significantly better survival in patients who received neoadjuvant chemotherapy than in those who did not receive neoadjuvant chemotherapy (log-rank test; $P = 0.039$).

In our experience, the benefit of neoadjuvant chemotherapy was difficult to assess because only 2 of the 24 patients received the treatment. Nevertheless, one of those patients survived longer than 5 years after surgery without recurrence and the other one remained alive at the end of this study period. Therefore, neoadjuvant chemotherapy seems to be a promising treatment to improve the survival of patients with gastric cancer who undergo PD.

Another therapeutic option for patients with initially incurable or unresectable gastric cancer is conversion

therapy, which is defined as surgical resection intending to achieve radical cure following chemotherapy and/or radiotherapy^[27]. Several studies have reported positive outcomes from this treatment^[28-32], although none of them evaluated conversion therapy for patients who underwent PD. As we previously demonstrated, PD has a high morbidity and mortality, and its survival benefit appears to be limited. Therefore, neoadjuvant chemotherapy and conversion therapy should be considered as an alternative treatment strategy for patients requiring PD for curative resection.

CONCLUSIONS

Although there is currently no solid evidence that PD may be recommended for advanced gastric cancer with pancreatic invasion when R0 resection is possible, but the high morbidity and mortality should be considered. In addition, multidisciplinary treatment, such as neoadjuvant chemotherapy, is anticipated to improve survival. Nevertheless, a large-scale multicenter cohort study is required to evaluate this highly invasive procedure.

DECLARATIONS

Authors' contributions

Designed the study, reviewed the literature, and wrote the manuscript: Makuuchi R

Contributed to writing the manuscript, drafting, critical revision, editing, and final approval of the final version: Terashima M

Contributed to critical revision of the manuscript and final approval of the final version: Irino T, Tanizawa Y, Bando E, Kawamura T

Availability of data and materials

Not applicable.

Financial support and sponsorship

This study was supported in part by a scientific research grant for multi-institutional trials to establish a new standard treatment for solid tumors in adults from the National Cancer Center Research and Development Fund (29-A-3).

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2018.

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65:87-108.
2. Katai H, Ishikawa T, Akazawa K, Isobe Y, Miyashiro I, Oda I, Tsujitani S, Ono H, Tanabe S, Fukagawa T, Nunobe S, Kakeji Y, Nashimoto A; Registration Committee of the Japanese Gastric Cancer Association. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). *Gastric Cancer* 2018;21:144-54.
3. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, Nagahori Y, Takahashi M, Kito F, Shimada H. Surgical outcomes in

- patients with T4 gastric carcinoma. *J Am Coll Surg* 2006;202:223-30.
4. Pacelli F, Cusumano G, Rosa F, Marrelli D, Dicosmo M, Cipollari C, Marchet A, Scaringi S, Rausei S, di Leo A, Roviello F, de Manzoni G, Nitti D, Tonelli F, Doglietto GB; Italian Research Group for Gastric Cancer. Multivisceral resection for locally advanced gastric cancer: an Italian multicenter observational study. *JAMA Surg* 2013;148:353-60.
 5. Maehara Y, Oiwa H, Tomisaki S, Sakaguchi Y, Watanabe A, Anai H, Sugimachi K. Prognosis and surgical treatment of gastric cancer invading the pancreas. *Oncology* 2000;59:1-6.
 6. Mita K, Ito H, Katsube T, Tsuboi A, Yamazaki N, Asakawa H, Hayashi T, Fujino K. Prognostic factors affecting survival after multivisceral resection in patients with clinical T4b gastric cancer. *J Gastrointest Surg* 2017;21:1993-9.
 7. Buchholtz TW, Welch CE, Malt RA. Clinical correlates of resectability and survival in gastric carcinoma. *Ann Surg* 1978;188:711-5.
 8. Yonemura Y, Ooyama S, Matumoto H, Kamata T, Kimura H, Takegawa S, Kosaka T, Yamaguchi A, Miwa K, Miyazaki I. Pancreaticoduodenectomy in combination with right hemicolectomy for surgical treatment of advanced gastric carcinoma located in the lower half of the stomach. *Int Surg* 1991;76:226-9.
 9. Hirose K, Onchi H, Iida A, Katayama K, Yamaguchi A, Nakagawara G. Surgical results of pancreaticoduodenectomy for carcinoma of the distal third of the stomach. *Int Surg* 1999;84:18-24.
 10. Ajsaka H, Fujita H, Kaji M, Maeda K, Yabushita K, Konishi K, Uchiyama A, Miwa A. Treatment of patients with gastric cancer and duodenal invasion. *Int Surg* 2001;86:9-13.
 11. Saka M, Mudan SS, Katai H, Sano T, Sasako M, Maruyama K. Pancreaticoduodenectomy for advanced gastric cancer. *Gastric Cancer* 2005;8:1-5.
 12. Lee HJ, Park do J, Lee KU. Pancreaticoduodenectomy for locally advanced gastric cancer. *Hepatogastroenterology* 2007;54:977-80.
 13. Chan WH, Cheow PC, Chung AY, Ong HS, Koong HN, Wong WK. Pancreaticoduodenectomy for locally advanced stomach cancer: preliminary results. *ANZ J Surg* 2008;78:767-70.
 14. Nunobe S, Hiki N, Ohyama S, Fukunaga T, Seto Y, Yamaguchi T. Survival benefits of pancreatoduodenectomy for gastric cancer: relationship to the number of lymph node metastases. *Langenbecks Arch Surg* 2008;393:157-62.
 15. Wang XB, Yang LT, Zhang ZW, Guo JM, Cheng XD. Pancreaticoduodenectomy for advanced gastric cancer with pancreaticoduodenal region involvement. *World J Gastroenterol* 2008;14:3425-9.
 16. Min JS, Jin SH, Park S, Kim SB, Bang HY, Lee JI. Prognosis of curatively resected pT4b gastric cancer with respect to invaded organ type. *Ann Surg Oncol* 2012;19:494-501.
 17. Ryu SY, Kim HG, Lee JH, Kim DY. Pancreaticoduodenectomy for advanced gastric carcinoma patients. *Acta Chir Belg* 2013;113:346-50.
 18. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205-13.
 19. Brar SS, Seevaratnam R, Cardoso R, Yohanathan L, Law C, Helyer L, Coburn NG. Multivisceral resection for gastric cancer: a systematic review. *Gastric Cancer* 2012;15 Suppl 1:S100-7.
 20. Tran TB, Worhunsky DJ, Norton JA, Squires MH 3rd, Jin LX, Spolverato G, Votanopoulos KI, Schmidt C, Weber S, Bloomston M, Cho CS, Levine EA, Fields RC, Pawlik TM, Maithel SK, Poultsides GA. Multivisceral resection for gastric cancer: results from the US gastric cancer collaborative. *Ann Surg Oncol* 2015;22 Suppl 3:S840-7.
 21. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. 1st English edition. Tokyo: Kanehara; 1995.
 22. Piso P, Bellin T, Aselmann H, Bektas H, Schlitt HJ, Klempnauer J. Results of combined gastrectomy and pancreatic resection in patients with advanced primary gastric carcinoma. *Dig Surg* 2002;19:281-5.
 23. Carboni F, Lepiane P, Santoro R, Lorusso R, Mancini P, Carlini M, Santoro E. Treatment for isolated loco-regional recurrence of gastric adenocarcinoma: does surgery play a role? *World J Gastroenterol* 2005;11:7014-7.
 24. Seevaratnam R, Cardoso R, McGregor C, Lourenco L, Mahar A, Sutradhar R, Law C, Paszat L, Coburn N. How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta-analysis. *Gastric Cancer* 2012;15 Suppl 1:S3-18.
 25. Cardoso R, Coburn N, Seevaratnam R, Sutradhar R, Lourenco LG, Mahar A, Law C, Yong E, Timmouth J. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. *Gastric Cancer* 2012;15 Suppl 1:S19-26.
 26. Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. *J Clin Oncol* 2007;25:2107-16.
 27. Terashima M. Conversion therapy for gastric cancer: who can make conversion as successful as Goromaru? *Gastric Cancer* 2016;19:685-6.
 28. Nakajima T, Ota K, Ishihara S, Oyama S, Nishi M, Ohashi Y, Yanagisawa A. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. *Ann Surg Oncol* 1997;4:203-8.
 29. Yano M, Shiozaki H, Inoue M, Tamura S, Doki Y, Yasuda T, Fujiwara Y, Tsujinaka T, Monden M. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer. *World J Surg* 2002;26:1155-9.
 30. Suzuki T, Tanabe K, Taomoto J, Yamamoto H, Tokumoto N, Yoshida K, Ohdan H. Preliminary trial of adjuvant surgery for advanced gastric cancer. *Oncol Lett* 2010;1:743-7.
 31. Satoh S, Okabe H, Teramukai S, Hasegawa S, Ozaki N, Ueda S, Tsuji A, Sakabayashi S, Fukushima M, Sakai Y. Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer. *Gastric Cancer* 2012;15:61-9.
 32. Fukuchi M, Ishiguro T, Ogata K, Suzuki O, Kumagai Y, Ishibashi K, Ishida H, Kuwano H, Mochiki E. Prognostic role of conversion surgery for unresectable gastric cancer. *Ann Surg Oncol* 2015;22:3618-24.